Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report

Cover Page

Cite item

Full Text

Abstract

Сytokine release syndrome is the common complication of CAR-T therapy. We report a case of patient with B-cell acute lymphoblastic leukemia developing сytokine release syndrome with shock and multiple organ failure and requiring cytokine removal and hemodiafiltration. Remission of the disease was achieved after CAR-T therapy.

About the authors

Antonina E. Shchekina

National Research Center for Hematology

Author for correspondence.
Email: shekina_ae@mail.ru
ORCID iD: 0000-0002-7916-2322

аспирант ОРИТ

Russian Federation, Moscow

Gennadii M. Galstyan

National Research Center for Hematology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0001-8818-8949

д-р мед. наук, зав. ОРИТ

Russian Federation, Moscow

Olga A. Gavrilina

National Research Center for Hematology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0002-9969-8482

канд. мед. наук, врач отд-ния интенсивной высокодозной химиотерапии гемобластозов

Russian Federation, Moscow

Natalia M. Arapova

National Research Center for Hematology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0002-6026-5989

врач группы диализа ОРИТ

Russian Federation, Moscow

Svetlana Iu. Bronyakina

National Research Center for Hematology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0003-1492-1735

врач экспресс-лаборатории ОРИТ

Russian Federation, Moscow

Ekaterina S. Kotova

National Research Center for Hematology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0002-7968-1923

аспирант

Russian Federation, Moscow

Vera V. Troitskaya

National Research Center for Hematology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0002-4827-8947

канд. мед. наук, зам. дир. по лечебной работе, зав. отд-нием высокодозной химиотерапии гемобластозов и депрессий кроветворения

Russian Federation, Moscow

Elena N. Parovichnikova

National Research Center for Hematology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0001-6177-3566

д-р мед. наук, зав. отд-нием химиотерапии гемобластозов, депрессий кроветворения и ТКМ

Russian Federation, Moscow

Mikhail A. Maschan

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0003-1735-0093

д-р мед. наук, врач-гематолог, зам. ген. директора – дир. Высшей школы молекулярной и экспериментальной медицины

Russian Federation, Moscow

Valerii G. Savchenko

National Research Center for Hematology

Email: shekina_ae@mail.ru
ORCID iD: 0000-0001-8188-5557

акад. РАН, д-р мед. наук, проф., генеральный дир.

Russian Federation, Moscow

References

  1. June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-5. doi: 10.1126/science.aar6711
  2. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-48. doi: 10.1056/nejmoa1709866
  3. Gutierrefz C, Brown ART, Herr MM, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care. 2020;58:58-64. doi: 10.1016/j.jcrc.2020.04.008
  4. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood and Marrow Transplant. 2019;25(4):625-38. doi: 10.1016/j.bbmt.2018.12.758
  5. Si S, Teachey DT. Spotlight on tocilizumab in the treatment of car-t-cell-induced cytokine release syndrome. Ther Clin Risk Manag. 2020;16:705-14. doi: 10.2147/TCRM.S223468
  6. Bottari G, Merli P, Guzzo I, et al. Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion. Crit Care Explor. 2020;2(1):e0071. doi: 10.1097/cce.0000000000000071
  7. Stahl K, Schmidt BMW, Hoeper MM, et al. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. J Crit Care. 2020;57:124-9. doi: 10.1016/j.jcrc.2020.02.010
  8. Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. Plos ONE. 2017;12(10):e018715. doi: 10.1371/journal.pone.0187015
  9. Magomedov MA, Kim TG, Masolitin SV, et al. Use of sorbent based on hypercrosslinked styrene-divinylbenzene copolymer with immobilized LPS-selective ligand in hemoperfusion for treatment of patients with septic shock. Obshchaya Reanimatologiya. 2021;16(6):31-53. doi: 10.15360/1813-9779-2020-6-31-53
  10. Bernardi MH, Rinoesl H, Dragosits K, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery – a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016;20(1):96. doi: 10.1186/s13054-016-1270-0
  11. Al Shareef K, Bakouri M. Cytokine Blood Filtration Responses in COVID-19. Blood Purif. 2020;50(2):141-9. doi: 10.1159/000508278
  12. Azoulay E, Shimabukuro-Vornhagen A, Darmon M, et al. Critical care management of chimeric antigen receptor T cell-related toxicity be aware and prepared. Am J Respir Crit Care Med. 2019;200(1):20-3. doi: 10.1164/rccm.201810-1945ED
  13. Azoulay E, Castro P, Maamar A, et al. Critical Care Management of CAR-T Cell Recipients: The CARTTAS International Study. Lancet Haematol. 2021;8(5):e355-64. doi: 10.1016/S2352-3026(21)00060-0
  14. Gutierrez C, McEvoy C, Mead E, et al. Management of the critically ill adult chimeric antigen receptor-t cell therapy patient: A critical care perspective. Crit Care Med. 2018;46(9):1402-10. doi: 10.1097/CCM.0000000000003258
  15. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531-44. doi: 10.1056/NEJMoa1707447
  16. Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30. doi: 10.1186/s13045-020-00856-8
  17. Gupta S, Seethapathy H, Strohbehn IA, et al. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020;76(1):63-71. doi: 10.1053/j.ajkd.2019.10.011
  18. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra45. doi: 10.1126/scitranslmed.3008226
  19. Liu S, Deng B, Yin Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10(2):15. doi: 10.1038/s41408-020-0280-y
  20. Ankawi G, Xie Y, Yang B, et al. What Have We Learned about the Use of Cytosorb Adsorption Columns? Blood Purif. 2019;48(3):196-202. doi: 10.1159/000500013
  21. Kogelmann K, Jarczak D, Scheller M, et al. Hemoadsorption by CytoSorb in septic patients: A case series. Crit Care. 2017;21(1):74. doi: 10.1186/s13054-017-1662-9

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Bone marrow cytology. May-Grunwald staining. Magnification 1000: a – before chimeric antigen receptor (CAR)-T cell therapy (CAR-T-therapy): 92% blast cells; b – on the 11th day after CAR-T therapy: 98,8% of lymphocytes.

Download (179KB)
Indexing metadata
3. Fig. 2. Dynamics of clinical and laboratory manifestations of CRS after infusion of CAR-T-lymphocytes.

Download (247KB)
Indexing metadata
4. Fig. 3. Connecting a hemofilter and a sorption apparatus "Efferon CT" with two devices.

Download (216KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies